How to access Mayzent from the UAE, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A UAE patient with relapsing forms of multiple sclerosis, especially active secondary-progressive MS, may receive a prescription for Mayzent (siponimod) from their treating neurologist. Mayzent is FDA-approved across the relapsing-MS spectrum and developed by Novartis. It is not a controlled substance. In the UAE, Mayzent is not routinely registered for outpatient dispensing, and access is typically coordinated through the named-patient import pathway.
This guide explains the pathway, documentation your physician prepares, typical timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Mayzent is an oral sphingosine-1-phosphate (S1P) receptor modulator taken once daily after a titration schedule. Critically, dosing selection and titration depend on CYP2C9 genotype, patients must be genotyped before initiation, and patients with the CYP2C93/3 genotype should not take Mayzent. Eligibility anchors to confirmed relapsing MS (including active SPMS) per McDonald criteria, baseline MRI, and the S1P-class cardiovascular, ophthalmologic, and infection monitoring plan. First-dose observation for bradycardia is standard per labeling.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Is Mayzent legally importable into the UAE?
Yes, through the UAE UAE Ministry of Health and Prevention (MoHAP) named-patient / special-access import framework. The mechanism permits an Emirati-licensed physician to import a medicine not locally registered when (a) it is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent registered alternative is suitable for the patient's active SPMS phenotype, (c) the physician accepts clinical responsibility, and (d) chain of custody is documented.
How the pathway works, step by step
- Consultation with your treating neurologist. MS diagnosis per McDonald criteria, active-SPMS characterisation, MRI documentation, and clinical rationale.
- CYP2C9 genotyping. Required before initiation to select appropriate dose or exclude patients with 3/3 genotype.
- Baseline assessment. CBC, hepatic panel, baseline ECG, ophthalmologic examination for macular oedema risk, varicella zoster antibody status, and first-dose observation plan.
- MoHAP named-patient application. The physician or hospital pharmacy files clinical rationale, patient reference, genotype result, titration schedule, and chain-of-custody commitment.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Mayzent from authorised distribution under DSCSA.
- Ambient shipment and arrival. Mayzent ships under controlled ambient conditions; the hospital pharmacy releases the bottle with the titration kit after first-dose observation is scheduled.
What documentation your physician needs
- Clinical rationale letter confirming relapsing MS / active SPMS and Mayzent as the indicated therapy
- Verification of the UAE medical license
- MRI report and McDonald-criteria documentation
- CYP2C9 genotype result
- Baseline CBC, hepatic panel, ECG, ophthalmologic examination, VZV antibody status
- First-dose observation plan
- Planned titration schedule and monitoring plan
Reserve Meds provides a physician documentation kit bundling templates MoHAP reviewers expect for S1P-modulator named-patient imports.
Costs and timing
Mayzent's US cash-pay drug-only reference cost sits in an indicative 2026 annual range of roughly USD 100,000-110,000 for continuous daily dosing. International logistics, MoHAP documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a transparent quote at the start of intake. Indicative range.
Indicative timing for first dispense after cohort intake opens is 7-14 days from the moment a complete MoHAP application is submitted, subject to the CYP2C9 genotyping result being in hand.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
Reserve Meds's role
- Sourcing. Through our US-licensed specialty wholesale partner under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and MoHAP review.
- Logistics. Ambient-controlled shipment to your prescribing hospital.
- Concierge case lead. A named point of contact coordinating monthly refills and the ongoing monitoring cadence.
What we do not do: We are not the prescriber, do not practise medicine, and are not the dispensing pharmacy. All clinical decisions remain with your treating neurologist.
Frequently asked
Is this legal in the UAE? Yes, when executed through the MoHAP named-patient framework with appropriate documentation. See our trust and compliance page.
Is Mayzent a controlled substance? No. Siponimod is not a scheduled controlled substance.
Why is CYP2C9 genotyping required? Mayzent metabolism is CYP2C9-dependent; dose selection is genotype-directed, and 3/3 patients should not take Mayzent per labeling. Your neurologist orders the test before initiation.
What is first-dose observation? Because S1P modulators can transiently lower heart rate, the first dose is administered under clinical observation for 6 hours with ECG monitoring, consistent with FDA labeling.
Will insurance cover this? Cash-pay is the default. Some UAE private insurers consider case by case; we supply documentation but do not process claims directly.
Next step
Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are not a pharmacy, not the prescriber, and not the manufacturer. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.
Clinical & regulatory review: Reserve Meds AI Clinical and Regulatory Review (see /trust). Last medically reviewed: 2026-04-23.
Frequently asked questions
How can I get Mayzent in the UAE if it is not approved or available there?
Reserve Meds coordinates US-sourced Mayzent for patients in the UAE through a physician-led, named-patient cross-border pathway. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for the UAE and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Mayzent in the UAE through named-patient or compassionate-use import?
Yes. Named-patient access (also called compassionate use or personal import) is the core route Reserve Meds operates for Mayzent. Eligibility and paperwork depend on the regulator in the UAE, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Mayzent in the UAE through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Mayzent to a patient in the UAE?
Reserve Meds sources Mayzent from a DSCSA-compliant US specialty supplier with full traceability and coordinates delivery to your treating physician or hospital pharmacy in the UAE, with appropriate handling for the product.
How long does it take, and what does Mayzent in the UAE cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Mayzent in the UAE?
Submit a 60-second intake through the Reserve Meds patient portal, or message the concierge team on WhatsApp. A named coordinator follows up within 24 hours.